🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Jiangsu Alphamab Biopharmaceuticals clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Jiangsu Alphamab Biopharmaceuticals as lead sponsor. Synced 26 Sep 2026
12Current trials
7Recruiting now
19Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Jiangsu Alphamab Biopharmaceuticals is the lead sponsor of 12 current clinical trials in our China register. 7 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are JSKN016, Docetaxel and Capecitabine. The most-studied condition is Advanced Malignant Solid Tumor.

ClinicalTrials.gov trials by status

  • Recruiting758%
  • Not yet open433%
  • Active, closed18%

Trials by phase

  • Phase 1542%
  • Phase 3325%
  • Phase 1/2325%
  • Phase 218%
01

Clinical trials sponsored by Jiangsu Alphamab Biopharmaceuticals

12 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
NCT06079983 · ClinicalTrials.gov ↗ · Breast Cancer
Phase 3 Recruiting 2023-12 China
Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC
NCT06868732 · ClinicalTrials.gov ↗ · Advanced Non-small Cell Lung Cancer
Phase 1 Recruiting 2025-04 China
Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer
NCT06942234 · ClinicalTrials.gov ↗ · Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer
Phase 1/2 Recruiting 2025-06 China
To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors
NCT06592417 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Tumor
Drug: JSKN016
Phase 1 Recruiting 2024-04 China
JSKN022 in Subjects With Advanced Malignant Solid Tumors
NCT07292402 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Tumors
Phase 1 Recruiting 2025-10 China
A Phase I Study of JSKN021 in Advanced Solid Tumors
NCT07617727 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Tumors
Phase 1 Recruiting 2026-06 China
A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
NCT07533123 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer
Phase 3 Recruiting 2026-03 China
A Study of JSKN027 in Patients With Advanced Solid Tumors
NCT07391644 · Advanced Malignant Solid Tumor
Phase 1 Not yet open 2026-03 China
JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer
NCT07797153 · ClinicalTrials.gov ↗ · Recurrent or Metastatic Cervical Cancer
Phase 3 Not yet open 2026-09 China
JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer
NCT07336771 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC)
Drugs: D-0502, JSKN016
Phase 1/2 Not yet open 2026-01 China
JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer
NCT07497074 · ClinicalTrials.gov ↗ · Cervical Cancer
Phase 2 Not yet open 2026-04 China
Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors
NCT05744427 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Drug: JSKN003
Phase 1/2 Active, closed 2023-03 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Jiangsu Alphamab Biopharmaceuticals trials

19 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Jiangsu Alphamab Biopharmaceuticals trials

12 conditions
Advanced Malignant Solid Tumor2Advanced Malignant Solid Tumors2Breast Cancer1Recurrent or Metastatic Cervical Cancer1Metastatic Breast Cancer1Locally Advanced Breast Cancer (LABC)1Advanced Non-small Cell Lung Cancer1Inoperable Locally Advanced HER2-Negative Breast Cancer1Metastatic HER2-Negative Breast Cancer1Cervical Cancer1Triple Negative Breast Cancer1Advanced Solid Tumor1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China127

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Advanced Malignant Solid Tumor

SponsorTrials
Minghui Pharmaceutical (Hangzhou)6
Sinocelltech2
Suzhou Maximum Bio-tech1

Sponsors with the most current trials registered for this condition.

06

Questions about Jiangsu Alphamab Biopharmaceuticals trials

How many clinical trials does Jiangsu Alphamab Biopharmaceuticals sponsor?

Jiangsu Alphamab Biopharmaceuticals is the lead sponsor of 12 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Jiangsu Alphamab Biopharmaceuticals trials recruiting?

Yes. 7 of its 12 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Jiangsu Alphamab Biopharmaceuticals testing?

Its current trials name 19 drugs and biologicals as interventions. The most frequent are JSKN016 (4), Docetaxel (3), Capecitabine (2), JSKN003 (2) and JSKN033 (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.